Prediction of the cumulated dose for external beam irradiation of prostate cancer patients with 3D-CRT technique

Abstract. Nowadays in radiotherapy, much effort is taken to minimize the irradiated volume and consequently minimize doses to healthy tissues. In our work, we tested the hypothesis that the mean dose distribution calculated from a few first fractions can serve as prediction of the cumulated dose distribution, representing the whole treatment. We made our tests for 25 prostate cancer patients treated with three orthogonal fields technique. We did a comparison of dose distribution calculated as a sum of dose distribution from each fraction with a dose distribution calculated with isocenter shifted for a mean setup error from a few first fractions. The cumulative dose distribution and predicted dose distributions are similar in terms of gamma (3 mm 3%) analysis, under condition that we know setup error from seven first fractions. We showed that the dose distribution calculated for the original plan with the isocenter shifted to the point, defined as the original isocenter corrected of the mean setup error estimated from the first seven fractions supports our hypothesis, i.e. can serve as a prediction for cumulative dose distribution.

Key words: 3D-CRT • cumulative dose • dose prediction • setup error • individualized margins

Introduction

The purpose of treatment planning is to deliver a high uniform dose to the clinical target volume (CTV), while sparing the normal tissues. In order to achieve this goal, much effort is undertaken to minimize a margin added to CTV, while creating planning target volume (PTV) [1]. There are several approaches to define the margin added to CTV. Two of them, proposed by van Herk [2] and Stroom [3], are in common use. These models are population-based models. To minimize the margin, the individualized methods of creating the margin are searched [4–6].

Our proposal leads to individualization of cumulative dose distribution. The work was performed for prostate patients because we had the full set of results of portal control for this group of patients. In the first step of our work, we decided to check our method for 3D cranial release technique (3D-CRT), which is easier to interpret. If our hypothesis is true, it would enable to individualize the CTV to PTV margin for each single patient.
Methods

For 25 patients with prostate cancer treated in our clinic with three fields 3D conformal radiotherapy technique (3D-CRT) (anterior-posterior field and two lateral wedged fields) orthogonal portal images have been taken each day of 25 fractions (2.6 Gy each). Patients had empty rectum and full bladder (they drank 0.5 l of water 30 min before adequate activity) during CT examination and irradiation as well. Knee-wedge support was used in order to provide better comfort and position reproducibility. CTV included prostate with seminal vesicles. PTV was created by adding following margins to the CTV: 7 mm in anterior-posterior and head-feet direction, 4 mm in left-right direction [7]. The setup errors, defined here as the difference between bones position with respect to the isocenter position during planning on digital radiographs (DRR) and images taken before irradiation on the daily basis, were measured for each fraction. In order to do that, orthogonal DRRs were prepared in the treatment planning system. They were compared with orthogonal kV and MV images taken before irradiation on the daily basis. The positions of the bones relative to the isocenter position were compared. Simplifying the scenario, we assumed that the target volume is not moving independently from bones. It was shown [7] that one can find a vector between the prostate shift and bones. That is why we did this simplification and took into account only bony shift, which allowed us to use planning CT for recalculations. The actual dose distribution for each fraction was calculated with the isocenter corrected for setup errors along each of the three axes. The number of monitor units (MUs), quantity related to dose and machine output, for each field was preserved as in the original plan. In other words, radiation produced by medical accelerator (in its shape, energy, dose rate, and delivery time) was preserved [6]. All calculations were done in Eclipse Treatment Planning System v. 10.0 (Varian Medical Co., Palo Alto, USA) with analytical anisotropic algorithm (AAA) (v. 10.0.28). Next we have calculated the sum of dose distributions obtained for each single fraction (cumulated dose distribution [CDD]) and we have also calculated the dose distribution representing the mean setup error on n-th first fractions (predicted cumulated dose distribution [PCDD] – PCDD2, PCDD5, PCDD10, PCDD20, PCDD25). The PCDD was calculated using the original plan with the isocenter placed at the point whose coordinates were calculated as the mean shift calculated over first 2, 3, …, 15, 20, and 25 fractions.

Each PCDD was compared with CDD in terms of the orthogonal profiles calculated in isocenter plane, i.e., anterior-posterior (AP), left-right (LR), and head-feet (HF) profile. The gamma index [8] with 3 mm and 3% was used. Calculations were performed in Scilab-based homemade program. According to methodology used in radiation therapy (RT) plan verification, we assumed that dose distributions were equal if 95% of analyzed points had gamma index value not larger than 1. Because the aim of the radiotherapy is to deliver the prescribe dose to the CTV, the planned dose distribution and the PCDD were also compared.

We used Kruskall-Wallis [9] and Kolmogorov-Smirnov [10] tests for comparison of CTV dose distribution (dose volume histograms [DVH]) between CDD and PCDD. The null hypothesis was that these distributions do not differ. In 1984, Brahme [11] showed that effective dose delivered to the target is well estimated by the mean dose if the dose distribution in the PTV is highly uniform, which is the case in prostate patient plan. Based on this idea, we tested the null hypothesis that the dose distribution in CTV for PCDD is the same as for CDD in terms of the mean dose to the CTV. Wilcoxon test was used for test this hypothesis. Additionally, we also analyzed the changes of the minimum dose in the CTV as it is still reported in 3D-CRT radiotherapy practice.

Results

For AP profile, the maximum gamma index (i.e., the maximum value of gamma index calculated in method described previously) was 2.52 for all patients and all PCDD. For 22 patients for the PCDD<sub>7</sub> to PCDD<sub>25</sub> the gamma index was always lower than 1.00. For LR profile, the maximum gamma index was 2.20. For 23 patients for the PCDD<sub>7</sub> to PCDD<sub>25</sub> the gamma index was not larger than 1.00. For HF profile, the maximum gamma index was 1.78. For 25 patients for the PCDD<sub>7</sub> to PCDD<sub>25</sub> the maximum gamma index was not larger than 1.00. The number of patients with gamma index less than 1.00 is less than 95% of points were: one patient for AP profile and PCDD to PCDD<sub>10</sub>, no patients for AP profile and PCDD<sub>2</sub> to PCDD<sub>25</sub>, one patient for LR profile and PCDD<sub>2</sub> to PCDD<sub>25</sub>, and one or no patients for HF profile and PCDD<sub>2</sub> to PCDD<sub>25</sub> (see Fig. 1).

Kruskall-Wallis and Kolmogorov-Smirnov tests showed that we can neglect the null hypothesis of similar dose distribution for at least half of the patients for N < 13 (see Figs. 2 and 3, which show the number of patients with p value larger than 0.01 for different values of N).

![Fig. 1. Number of patients with gamma index < 1 in less than 95% of points for AP, LR and HF profile, PCDD and CDD comparison.](attachment:image.png)
We used the Wilcoxon signed ranked test with statistical significance of 0.1 for two sets of data – once for absolute mean dose values and once for percent dose values rounded to one-digit value. The result was that we have to decline the null hypothesis of no significant difference between mean values of CTV dose for PCDD20 and PCDD25 for the first method and for PCDD25 for the second method.

In almost all cases, the predicted minimum dose in CTV was lower than minimum dose for cumulated dose distribution. For all PCDDN, the predicted minimum dose in CTV was higher than 97% of dose for at least 75% of patients. Only single outsiders have predicted minimum dose less than 95%. In Fig. 4, the difference between CDD and PDDN in terms of the minimum dose to the CTV is presented. In Fig. 5 the predicted minimum dose to the CTV for different N is given. The maximum dose for cumulative dose distribution never differs from the maximum dose for clinical treatment plan of more than 1%.

Discussion

Our hypothesis was that it is possible to predict the final cumulated dose distribution after first few fractions. From our results, we can see that in fact after calculation of mean shift for seven first fractions, we can predict CDD fairly well. Also minimum dose to CTV is predicted properly.

Our statistical comparison of CTV dose distribution showed compatibility for half of patients (Kolmogorov-Smirnov test). However, paired t-test is usually used in similar studies, we think that nonparametric Wilcoxon signed ranked test is better suited for to test the hypothesis that the distribution in CTV for PCDDN is the same as for CDDN in terms of mean dose in CTV [12]. This is due to the fact that dose distribution in CTV is not normal. We can see that PCDD20 and PCDD25 disagreed our null hypothesis. To our surprise, the differences of mean doses between PCDD20, PCDD25 and CDD were statistically significant. However, they were very small, less than 0.2%. Such small differences have negligible influence on treatment outcome.
Our study was limited only to 3D-CRT technique, but we can guess that for other techniques such as intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) due to the higher dose gradient at the PTV border and higher low dose volume, the results might be similar as for 3D-CRT. Testing our method for other techniques will be a further step in our investigation.

It should be mentioned that in case of prostate its movement with respect to bony anatomy influences the cumulated dose distribution but the aim of this study was to test whether proposed method may be applied for targets for which internal movement is negligible. The results of this work may be applied for all these clinical situations were there the setup error is the main factor influencing on the dose distribution and if the dose distribution of setup errors is similar to the one obtained for prostate. We think that it may be applied for the brain patients. The individualization of the margin will be addressed in the next paper.

**Conclusion**

If we know setup errors for first seven fractions, the prediction of the cumulated dose distribution is quite robust. Based on the estimation of the cumulative dose distribution, the methods of margin individualization may be searched.

**References**


